Milestone Pharmaceuticals (MIST) Stock: FDA Approval of CARDAMYST, Launch Timeline, and Analyst Forecasts (Dec. 15, 2025)

Milestone Pharmaceuticals Inc. entered a new phase in its corporate life this month: from clinical-stage story stock to a company with an FDA-approved, commercially launchable cardiovascular product. The catalyst is CARDAMYST™ nasal spray, now approved in the U.S. for adults experiencing acute symptomatic episodes of paroxysmal supraventricular tachycardia—a rapid heart rhythm disturbance that can be frightening, disruptive, and costly when it sends patients to emergency care. GlobeNewswire

NASDAQ:MIST · Pharmaceutical Industry
Milestone Pharmaceuticals (MIST) Stock Update: FDA Approves CARDAMYST (Etripamil) — This Week’s Volatility, Analyst Forecasts, and What to Watch Next (Updated Dec. 12, 2025)

Milestone Pharmaceuticals (MIST) Stock Update: FDA Approves CARDAMYST (Etripamil) — This Week’s Volatility, Analyst Forecasts, and What to Watch Next (Updated Dec. 12, 2025)

Milestone Pharmaceuticals Inc. closed out the week in the spotlight after the company announced U.S. FDA approval of CARDAMYST™—positioning Milestone to transition from a development-stage biotech to a commercial-stage cardiovascular company. GlobeNewswire+1
14 December 2025
··
Milestone Pharmaceuticals (MIST) Stock This Week: FDA Approves CARDAMYST, Shares Whipsaw Into the Weekend — Week Ahead Outlook (Updated Dec. 13, 2025)

Milestone Pharmaceuticals (MIST) Stock This Week: FDA Approves CARDAMYST, Shares Whipsaw Into the Weekend — Week Ahead Outlook (Updated Dec. 13, 2025)

Milestone Pharmaceuticals Inc. just crossed the line that separates “clinical-stage story stock” from “commercial execution stock.” Late Friday, the company announced FDA approval of CARDAMYST™—a self-administered nasal spray for adults to convert acute symptomatic episodes of paroxysmal supraventricular tachycardia to sinus rhythm. GlobeNewswire
13 December 2025
··
Milestone Pharmaceuticals (MIST) Stock in Focus on Dec. 12, 2025: FDA Decision Countdown, Latest News, Analyst Forecasts, and Key Risks

Milestone Pharmaceuticals (MIST) Stock in Focus on Dec. 12, 2025: FDA Decision Countdown, Latest News, Analyst Forecasts, and Key Risks

Milestone Pharmaceuticals Inc. stock is drawing heightened attention on December 12, 2025 , as investors position ahead of a make-or-break FDA decision for the company's lead program, CARDAMYST™ nasal spray , aimed at treating paroxysmal supraventricular tachycardia . The regulatory catalyst arrives after a volatile year that included an FDA Complete Response Letter earlier in 2025, followed by the FDA's acceptance of Milestone's resubmission and a new target action date set for mid-December.GlobeNewswire+ 2GlobeNewswire+ 2
12 December 2025
·
Follow on Google News
Add as preferred source Open in Google News